Also this morning, DPII's Xenometrix gets a win of undisclosed (probably small) size.
>>Xanthon Inc. announced today that it has obtained a worldwide license from Xenometrix, Inc., a wholly owned subsidiary of Discovery Partners International, Inc., (Nasdaq: DPII - news) for access to gene expression profiling claims in United States and European patents. The non- exclusive license covers the collection of gene expression profiles utilizing all platforms including biochips, high-density microarrays and other high- throughput methods.
Jim Skinner, President and CEO of Xanthon, said, ``The combination of our patented electrochemical detection technology and the gene expression profiling patents from Xenometrix enables Xanthon to expand our range of products and pursue additional high-growth opportunities within drug discovery and other gene-based applications such as disease pathway characterization and toxicology assessment.'' Xanthon and Xenometrix have agreed to keep licensing terms confidential.
Xanthon, a bioinformation solutions company, has developed a patented, high-throughput electrochemical platform for the direct detection of nucleic acids and proteins that eliminates the need for sample purification, amplification or the addition of chemical labels. The Company's first product, the XANTHON XPRESSION ANALYSIS SYTEM(TM), will be released early next year to the drug discovery marketplace for high-throughput, multiplexed expression analysis. Future Xanthon products will include the XANTHON SNP ANALYSIS SYSTEM(TM) and the XANTHON PROTEOMICS ANALYSIS SYSTEM(TM).
Xenometrix's proprietary gene profiling technology provides important efficacy and safety data with regard to a compound's potential therapeutic and toxic effects, allowing scientists to streamline the drug development process. Xenometrix has granted non-exclusive licenses to over 20 companies who are leaders in different aspects of genomics. Discovery Partners acquired Xenometrix in May 2001 to enhance its in-vitro assay development and toxicology services. Discovery Partners is focused on providing the best platforms, services and information available to complement the internal drug discovery efforts of pharmaceutical and biopharmaceutical companies in the post-genomics era. Discovery Partners is headquartered in San Diego, California and has operations in San Diego, South San Francisco, Tucson, AZ, Fort Lee, NJ, Boulder, CO and Basel, Switzerland. <<
snip
Cheers, Tuck |
